Table 2. Comparisons of demographical data, clinicopathological characteristics, treatment information and survival data in parathyroid carcinoma patients receiving LND versus not receiving LND in the entire and the PSM cohort 2.
| Variables | The entire cohort 2 | The PSM cohort 2 | |||||||
|---|---|---|---|---|---|---|---|---|---|
| All (n=215) | LND – (n=146) | LND + (n=69) | P value | All (n=167) | LND – (n=104) | LND + (n=63) | P value | ||
| Age (years) | 0.56 | 0.89 | |||||||
| ≤66 | 163 (75.8) | 109 (74.7) | 54 (78.3) | 125 (74.9) | 77 (74.0) | 48 (76.2) | |||
| >66 | 52 (24.2) | 37 (25.3) | 15 (21.7) | 42 (25.1) | 27 (26.0) | 15 (23.8) | |||
| Sex | 0.62 | >0.99 | |||||||
| Female | 105 (48.8) | 73 (50.0) | 32 (46.4) | 77 (46.1) | 48 (46.2) | 29 (46.0) | |||
| Male | 110 (51.2) | 73 (50.0) | 37 (53.6) | 90 (53.9) | 56 (53.8) | 34 (54.0) | |||
| Race | 0.24 | 0.98 | |||||||
| White | 156 (72.6) | 101 (69.2) | 55 (79.7) | 129 (77.2) | 80 (76.9) | 49 (77.8) | |||
| African American | 37 (17.2) | 29 (19.9) | 8 (11.6) | 22 (13.2) | 14 (13.5) | 8 (12.7) | |||
| Others | 22 (10.2) | 16 (11.0) | 6 (8.7) | 16 (9.6) | 10 (9.6) | 6 (9.5) | |||
| Year of diagnosis | 0.17 | 0.89 | |||||||
| 2004–2008 | 74 (34.4) | 55 (37.7) | 19 (27.5) | 51 (30.5) | 32 (30.8) | 19 (30.2) | |||
| 2009–2013 | 74 (34.4) | 51 (34.9) | 23 (33.3) | 56 (33.5) | 36 (34.6) | 20 (31.7) | |||
| 2014–2018 | 67 (31.2) | 40 (27.4) | 27 (39.1) | 60 (35.9) | 36 (34.6) | 24 (38.1) | |||
| Tumor size (mm) | 0.28 | 0.36 | |||||||
| ≤40 | 177 (82.3) | 123 (84.2) | 54 (78.3) | 137 (82.0) | 88 (84.6) | 49 (77.8) | |||
| >40 | 38 (17.7) | 23 (15.8) | 15 (21.7) | 30 (18.0) | 16 (15.4) | 14 (22.2) | |||
| Grade | 0.10 | 0.87 | |||||||
| Grade I | 19 (8.8) | 15 (10.3) | 4 (5.8) | 11 (6.6) | 7 (6.7) | 4 (6.3) | |||
| Grade II–IV | 8 (3.7) | 3 (2.1) | 5 (7.2) | 4 (2.4) | 2 (1.9) | 2 (3.2) | |||
| Unknown/blank | 188 (87.4) | 128 (87.7) | 60 (87.0) | 152 (91.0) | 95 (91.3) | 57 (90.5) | |||
| Stage | 0.39 | 0.75 | |||||||
| Localized | 140 (65.1) | 98 (67.1) | 42 (60.9) | 106 (63.5) | 67 (64.4) | 39 (61.9) | |||
| Regional | 65 (30.2) | 43 (29.5) | 22 (31.9) | 53 (31.7) | 33 (31.7) | 20 (31.7) | |||
| Distant | 10 (4.7) | 5 (3.4) | 5 (7.2) | 8 (4.8) | 4 (3.8) | 4 (6.3) | |||
| Primary surgery | 0.85 | 0.99 | |||||||
| Radical surgery | 86 (40.0) | 59 (40.4) | 27 (39.1) | 65 (38.9) | 41 (39.4) | 24 (38.1) | |||
| Others | 129 (60.0) | 87 (59.6) | 42 (60.9) | 102 (61.1) | 63 (60.6) | 39 (61.9) | |||
| Lymph node status | – | – | |||||||
| Positive | – | – | 6 (8.7) | – | – | 6 (9.5) | |||
| Negative | – | – | 56 (81.2) | – | – | 50 (79.4) | |||
| Unknown | – | – | 7 (10.1) | – | – | 7 (11.1) | |||
| Radiotherapy | 0.04 | 0.45 | |||||||
| Yes | 31 (14.4) | 16 (11.0) | 15 (21.7) | 26 (15.6) | 14 (13.5) | 12 (19.0) | |||
| Others | 184 (85.6) | 130 (89.0) | 54 (78.3) | 141 (84.4) | 90 (86.5) | 51 (81.0) | |||
| Survival status | 0.87 | 0.34 | |||||||
| Alive | 177 (82.3) | 121 (82.9) | 56 (81.2) | 141 (84.4) | 91 (87.5) | 50 (79.4) | |||
| Dead from PC | 13 (6.0) | 8 (5.5) | 5 (7.2) | 11 (6.6) | 6 (5.8) | 5 (7.9) | |||
| Dead from other causes | 25 (11.6) | 17 (11.6) | 8 (11.6) | 15 (9.0) | 7 (6.7) | 8 (12.7) | |||
| Survival time (months) | 65.0 (1.0–179.0) |
75.5 (1.0–179.0) |
60.0 (2.0–177.0) |
0.11 | 63.0 (2.0–178.0) |
65.5 (1.0–178.0) |
60.0 (2.0–177.0) |
0.25 | |
| CSS (log-rank test), % | 0.43 | 0.45 | |||||||
| 5-year survival | 95.2 | 96.8 | 91.4 | 96.5 | 96.5 | 90.6 | |||
| 10-year survival | 89.0 | 89.7 | 88.4 | 89.7 | 87.8 | 87.4 | |||
Data are expressed as number (percentage) or median (range). LND, lymph node dissection; PSM, propensity score matching; PC, parathyroid carcinoma; CSS, cancer-specific survival.